Naslov
Intravitreal bevacizumab (Avastin) in treatment of neovascular age-related macular degeneration

Autori
Lazić, Ratko ; Gabrić, Nikica ; Dekaris, Iva ; Sarić, Borna ; Gavrić, Morena

Izvornik
Collegium antropologicum (0350-6134) 31 (2007), Suppl. 1; 77-81

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
bevacizumab; age related macular degeneration

Sažetak
To evaluate the efficacy and safety of intravitreal bevacizumab in treatment of minimally classic and occult choroidal neovascularization secondary to age-related macular disease 48 eyes of 48 patients (mean age of 74.8) included in this prospective, noncomparative, interventional case series. Median follow-up was 18 weeks (6-24). Intravitreal bevacizumab injection of 0.05 mL (1.25 mg) was administered at baseline and in 6 week intervals until leakage resolved, and repeated in case of leakage recurrence. Visual acuity (VA) improved in the majority of patients (mean baseline VA=1.078 log MAR) by mean increase of 1.32 lines (last follow-up) (p=0.001). Central foveal thickness and total macular volume decreased by 51 mu m (p=0.01) and 0.84 mm(3) (p < 0.0001) respectively. No serious complications were observed. As initial therapy, intravitreal bevacizumab appears to be safe and effective. A significant functional and anatomical improvement was noted in majority of patients and maintained during follow-up.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA